Navigation Links
Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
Date:1/29/2008

Results from two separate Phase 1 studies show sobetirome, a selective

thyroid hormone receptor beta agonist, reduced levels of low-density

lipoprotein versus placebo

ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company developing compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced results from two Phase 1 clinical studies with its novel lipid lowering compound, sobetirome (formerly QRX-431), in development for the treatment of elevated LDL cholesterol (also known as "bad cholesterol") levels. The results of the studies indicated LDL lowering with both single and multiple doses of sobetirome in a healthy volunteer population not enriched for elevated LDL levels. Sobetirome was generally well tolerated in both studies. Sobetirome is a new selective thyroid hormone receptor beta agonist that may activate reverse cholesterol transport.

"We are excited and extremely encouraged by these Phase 1 results indicating that sobetirome was generally well tolerated and showed lowering of LDL levels. We look forward to replicating these results in larger Phase 2 and 3 trials. We believe this new compound has potential as monotherapy or in combination with statins for the many patients who are unable to tolerate current therapies or who fail to achieve lipid treatment goals with statins alone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx.

Study Results

Lipid-lowering effects in both single and multiple doses were seen in the randomized, double-blind, placebo-controlled Phase 1 studies of sobetirome. In the single dose study of 32 subjects, low-density lipoprotein (LDL) cholesterol levels decreased by up to 22% in subjects receiving up to 450 micrograms of sobetirome, compared to 2% in subjects who received placebo. The greatest reductions were observed 72 hours after dosing. In
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
5. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
6. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
7. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
10. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
11. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...ept. 4 /- SleepQuest has partnered,wi...ment for,sleep-disordered breathing, to conduct cl... monitor patients with Obstructive Sleep Apnea fro...tended to more easily,provide data that can be use...ng PAP treatment., "We take pride in working with...
(Date:9/4/2008)...4 /- Insmed Inc. (Nasdaq:,I...rmaceuticals, today,announced that Geoffrey Allan,...m Asia 2008 Conference. Dr Allan will be discussin...atory issues surrounding follow-on,biologics (FOB)...uesday,September 9, 2008 at the Sheraton Towers Ho...
(Date:9/4/2008)...e Symbol: MS, EDMONTON, Sept. 4 /PRNewswire-First...eveloper in the treatment of multiple sclerosis (M...tration (FDA) of the United States,has granted fas...irucotide,(MBP8298), for the treatment of secondar...urrently being evaluated in a U.S. pivotal phase I...
(Date:9/4/2008)... 4 /- Repligen Corporation,...has received $1.125 million,in research grants to ...dreich,s ataxia. The grants are comprised of $1 mi...) and $125,000 from the Friedreich,s,Ataxia Resear...ation (NAF).,The grants will further the developme...
Breaking Biology Technology:Latest Sleep Disorder Technology Tested With SleepQuest 2Insmed to Present at BioPharm Asia 2008 Conference 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 2Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 3Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 4Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 5
... Nettles Cory Nettles, secretary of Wisconsins De... resign from his post on December 31 to become a p...office. , ,Nettles has served in Governor Jim Doy...rning to the firm he worked at before Doyle appoin...nor Doyle as a leader, a boss, and a friend, he sa...
...children, December is full of excitement and antic...g. For me, December is equally exciting, as I scre...ace at February,s DEMO@15 show. While you have t... so companies that will debut at the show, there a...til the conference gems we can unwrap now. , ,One...
...ou havent ever read the opening passages of Alice...d, in 1865, to write a pretty accurate description...rabbit rushing by, very late for a very important ...n of the rabbit hole or opportunity, and unavailab...g, almost hallucinogenic quality of a workload rus...
...on, Wis. Recently UW researchers have put enough...ad spin, addressed shockwaves in fusion reactors w... hungry. Interested? Read on. , Monitor predicts e... monitor on a bicycle, add devices that measure th...ythm created by their peddling, record it all at t...
Other Biology Technology:Secretary Nettles leaving Commerce for law practice 2Secretary Nettles leaving Commerce for law practice 3An early Christmas gift 2The IT drug Just say no? 2The IT drug Just say no? 3A week in UW research: fusion, racing and sleep 2A week in UW research: fusion, racing and sleep 3
(Date:9/4/2008)...pt. 4, 2008) A variety of organismsfrom bacteria...ythms, where the timing and duration of fundamenta...low them to adapt and survive, even under fluctuat...gnificant advances have been made to understand th...anslate into modifications in cellular physiology ...
(Date:9/4/2008)... German . , Cystic kidney disease, renal fibros...excretory organs are characterized by overproducti...proteins in the renal cells. An international rese...DKFZ and Heidelberg University Hospitals has now d...se conditions. , The researchers introduced a g...
(Date:9/4/2008)... Breast Cancer Symposium features the latest cutti...clinical breast cancer research. This year,s meeti...ches, as well as strides being made in diagnosing ... the best advantage of the symposium,s scientific ... to visit www.sabcs.org to view the new press po...
(Date:9/4/2008)...ut aside their competitive interstate rivalry to c...ounced by Innovation Minister Gavin Jennings and N...ty Firth, today. , Scientists from the Monash I... from New South Wales will compare two different m...matic cell nuclear transfer (SCNT) and induced plu...
Breaking Biology News(10 mins):Interdisciplinary volume on biological rhythms serves as both primer and in-depth resource 2Gaining a better understanding of kidney diseases 2Stem cell research puts interstate rivalry on hold 2GBIF making the search for biodiversity research resources easier 1464 1GBIF making the search for biodiversity research resources easier 1464 2Amarin Signs Agreement to Acquire Ester Neurosciences 2072 1Amarin Signs Agreement to Acquire Ester Neurosciences 2072 2Amarin Signs Agreement to Acquire Ester Neurosciences 2072 3Amarin Signs Agreement to Acquire Ester Neurosciences 2072 4Amarin Signs Agreement to Acquire Ester Neurosciences 2072 5Amarin Signs Agreement to Acquire Ester Neurosciences 2072 6Amarin Signs Agreement to Acquire Ester Neurosciences 2072 7Amarin Signs Agreement to Acquire Ester Neurosciences 2072 8Amarin Signs Agreement to Acquire Ester Neurosciences 2072 9Amarin Signs Agreement to Acquire Ester Neurosciences 2072 10Amarin Signs Agreement to Acquire Ester Neurosciences 2072 11Celtic Pharma Provides Update on XERECEPT 28R 29 Clinical Program 981 1Celtic Pharma Provides Update on XERECEPT 28R 29 Clinical Program 981 2Celtic Pharma Provides Update on XERECEPT 28R 29 Clinical Program 981 3Celtic Pharma Provides Update on XERECEPT 28R 29 Clinical Program 981 4World class in Systems Biology is the aim 1462 1World class in Systems Biology is the aim 1462 2World class in Systems Biology is the aim 1462 3World class in Systems Biology is the aim 1462 4
...patients with a blood disorder called polycythemia... at the University of California, San Diego (UCSD)...erative Medicine and Comprehensive Cancer Center a...irmed. , The discovery suggests that development o..., to interfere with the pathway leading to the dis...
...ient genes, scientists have for the first time rec...y "irreducibly complex" molecular system. , The re...r of biology at the University of Oregon,s Center ...published in the April 7 issue of SCIENCE. , How ...ex molecular systems ?those in which the function ...
...n groups battling global extinctions has saved one...d species. , American Bird Conservancy (ABC), Cons... of Colombia stepped in to protect the 1,600-acre ...e Santa Marta massif, on the Caribbean coast of Co... , The site is the sole breeding ground for the G...
...r and the Manchester Metropolitan University have ... of ancient spiders trapped in amber more than 30 ...ers from the Baltic (Poland) and the Dominican (Ca...e ecologies of spiders dating back to the Cenozoic...rom different parts of the world have been compare...
Other Biology News:Mutation in blood stem cells provides clues to cancer development 2Mutation in blood stem cells provides clues to cancer development 3Evolution of 'irreducible complexity' explained 2Crucial site for endangered frogs and birds saved 2Amber reveals ecology of 30 million year old spiders 2
...OP9 signalosome complex (CSN), a complex involved ...he CSN complex is an essential regulator of the ub... deneddylation of the cullin subunits of SCF-type ...in phosphorylation of p53/TP53, c-jun/JUN, IkappaB...
6B9
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2
Biology Products: